secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-10-09T21:15:59+00:00
Accession:  0001628280-26-065559
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vistagen board amends executive severance plan; severance now payable without Cause outside CIC
--------------------------------------------------------------------------------

- Board approved an amended and restated Executive Severance Plan on Oct 7, 2026, superseding the Change in Control Executive Severance Plan adopted Aug 11, 2026.
- Severance now applies to involuntary terminations without Cause even absent a Change in Control, per the plan effective Oct 7, 2026.
- Qualifying Termination window runs from 3 months before to 18 months after a Change in Control; employees need 12 months of full-time service to qualify.
- CIC qualifying terminations add full equity acceleration (performance awards at target) and a lump sum of target annual bonus times the Bonus Severance Period.
- CEO Shawn K. Singh is deemed an Eligible Employee for Section 6(c) equity acceleration despite his Individual Agreement; all current executive officers are covered.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026065559/0001628280-26-065559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026065559/vtgn-20261007.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-065559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer